Enhancing cancer treatment using natural killer cells in dogs with soft tissue sarcoma
Official title: Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model
Funded at Northwestern University at Chicago · NIH-11166856 · Data updated 2026-11-12
This study is looking at a new way to help treat soft tissue sarcoma in dogs by using special immune cells called natural killer cells, along with a targeted antibody, to make the treatment more effective and hopefully improve outcomes for our furry friends.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $672,844 |
| NIH project number | 1R01CA290719-01A1 |
| Project ID | NIH-11166856 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are dogs diagnosed with soft tissue sarcoma that may benefit from enhanced immune therapies.
✕Less likely to help
Patients who do not have soft tissue sarcoma or those with other types of cancer may not receive any benefit from this research.
What this research studies
This research investigates how to improve cancer therapy by using natural killer (NK) cells, which are a type of immune cell, in the treatment of soft tissue sarcoma in dogs. The study focuses on a specific antibody that targets a molecule called MIC, which is found in many solid tumors. By using this antibody, the researchers aim to enhance the effectiveness of NK cells in attacking cancer cells, potentially leading to better outcomes for patients. The approach involves testing this therapy in a canine model to better understand its effects before considering human applications.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for both dogs and potentially humans by improving the immune response against tumors.
How similar studies have gone: Previous research has shown promise in using NK cells for cancer treatment, but this specific approach targeting MIC in a canine model is relatively novel.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Pollack, Seth M — Northwestern University at Chicago
- Study coordinator: Pollack, Seth M
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Soft Tissue Sarcoma: targeted therapies and biomarkers to help patients
A big research effort at a major cancer center aims to develop targeted treatments and biomarkers to improve outcomes for people with soft tissue sarcoma.
-
Ultra-steerable ultrasound therapy for soft tissue sarcoma
A new ultrasound device is being developed to non-invasively shrink or remove soft tissue sarcomas while protecting nearby nerves, blood vessels, and bones.
-
Robotic ultrasound system to non-invasively remove soft tissue sarcoma
A robotic ultrasound approach aims to precisely destroy soft tissue sarcoma tumors without open surgery for people with large or hard-to-reach tumors.
-
Boosting NK-cell therapy for soft tissue sarcoma using a dog model
This project combines an antibody that soaks up a tumor-made immune blocker with natural killer (NK) cell therapy to help dogs and, eventually, people with soft tissue sarcoma fight their tumors.
-
Targeted treatments for soft tissue sarcoma
This project is testing targeted drugs and immunotherapies for people with soft tissue sarcoma, including adults and children.
-
Non-invasive treatment for soft tissue sarcoma using ultrasound technology
This study is testing a new ultrasound treatment that gently breaks down tough tumors in soft tissues, making it easier for patients with hard-to-reach sarcomas to manage their cancer without needing surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.